← Back to Search

Antiviral

Foscarnet for CMV Retinitis in AIDS

N/A
Waitlist Available
Research Sponsored by Astra USA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients presenting with a baseline absolute neutrophil count < 750 cells/mm3 or baseline platelet count < 50000 platelets/mm3 will be categorized as ineligible to receive ganciclovir induction therapy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing foscarnet as a possible treatment for CMV retinitis in AIDS patients who can't take ganciclovir due to myelosuppression or who have not responded to it.

Who is the study for?
This trial is for AIDS patients with CMV retinitis who can't use ganciclovir due to severe side effects like low blood cell counts or because it didn't work for them. They must be able to consent and not have allergies to foscarnet, significant lung/brain issues, or eye conditions that block vision checks.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of a drug called Foscarnet as an initial treatment for CMV retinitis in those where Ganciclovir failed. It also looks at how long the treatment works, its impact on CMV levels in blood/urine, and HIV p24 antigen recovery.See study design
What are the potential side effects?
Foscarnet may cause kidney problems, changes in mineral levels in your blood (like calcium), nausea, seizures if minerals get too low/high, and general discomfort at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My neutrophil count is above 750 and my platelet count is above 50,000.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Astra USALead Sponsor
9 Previous Clinical Trials
311 Total Patients Enrolled
4 Trials studying Cytomegalovirus Retinitis
142 Patients Enrolled for Cytomegalovirus Retinitis

Media Library

Foscarnet (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT00002301 — N/A
Cytomegalovirus Retinitis Research Study Groups:
Cytomegalovirus Retinitis Clinical Trial 2023: Foscarnet Highlights & Side Effects. Trial Name: NCT00002301 — N/A
Foscarnet (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002301 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the trial protocol allow for people 45 years or older to participate?

"Patients that meet the criteria of this clinical trial must be between 18 and 65 years old. There are 311 studies available for adolescents, while 955 studies have been created accomodate elderly patients."

Answered by AI
~233 spots leftby Mar 2025